Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
First Claim
Patent Images
1. A monoclonal antibody that binds to an epitope on PCSK9, wherein the epitope comprises at least one of the following residues:
- S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ ID NO;
3, and wherein said monoclonal antibody comprises;
a heavy chain variable region; and
a light chain variable region;
wherein the monoclonal antibody blocks binding interaction between PCSK9 and EGFa domain of LDLR.
1 Assignment
0 Petitions
Accused Products
Abstract
Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
153 Citations
23 Claims
-
1. A monoclonal antibody that binds to an epitope on PCSK9, wherein the epitope comprises at least one of the following residues:
- S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ ID NO;
3, and wherein said monoclonal antibody comprises;a heavy chain variable region; and a light chain variable region;
wherein the monoclonal antibody blocks binding interaction between PCSK9 and EGFa domain of LDLR. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)
- S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ ID NO;
-
10. A pharmaceutical composition comprising:
-
a pharmaceutically acceptable carrier; and a monoclonal antibody that binds to an epitope on PCSK9, wherein the epitope comprises at least one of the following residues;
S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ ID NO;
3, and wherein said monoclonal antibody comprisesa heavy chain variable region and a light chain variable region;
wherein the monoclonal antibody blocks binding interaction between PCSK9 and EGFa domain of LDLR. - View Dependent Claims (21, 22, 23)
-
Specification